Dimenhydrinate

Identification

Summary

Dimenhydrinateis a medication used to prevent and treat nausea, vomiting, vertigo, and motion sickness.

Brand Names

Dramamine, Driminate, Gravol

Generic Name

Dimenhydrinate

DrugBank Accession Number

DB00985

Background

Dimehydrinate was first described in the literature in 1949,⁵and patented in 1950.¹¹Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.⁷

Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.^9,10,11Dimenhydrinate is a combination ofDiphenhydramineand8-chlorotheophyllinein a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline.¹⁰

The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system²while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.³

When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.¹

Dimenhydrinate was granted FDA approval on 31 May 1972.⁸

Type

Small Molecule

Groups

Approved

Structure

Download

MOL SDF PDB SMILES InChI

Similar Structures

Structure for Dimenhydrinate (DB00985)

×

Close

Weight

Average: 469.97
Monoisotopic: 469.1880675

Chemical Formula

C₂₄H₂₈ClN₅O₃

Synonyms

• (O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
• 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
• Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
• Dimenhidrinato
• Dimenhydrinate
• Dimenhydrinatum
• diphenhydramine 8-chlorotheophyllinate
• diphenhydramine 8-chlorotheophylline
• Diphenhydramine theoclate
• N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
• O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate
• β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine

Pharmacology

Indication

Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.^9,10

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Dizziness
• Labyrinthine disorder
• Menière's Disease
• Morning Sickness
• Motion Sickness
• Nausea
• Nausea and vomiting
• Post Operative Nausea and Vomiting (PONV)
• Radiation-Induced Nausea and Vomiting
• Vertigo
• Vomiting

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.^9,10It has a short duration of action of 4-8 hours.⁴Patients should be counselled regarding pronounced drowsiness, avoiding alcohol and other sedatives, and exercising caution when operating a motor vehicle or heavy machinery.⁹

Mechanism of action

Dimenhydrinate is a theoclate salt that separates intodiphenhydramineand8-chlorotheophylline.^10,13While the exact mechanism of action is unknown, diphenhydramine is theorized to reduce disturbances to equilibrium through antimuscarinic effects or histamine H1 antagonism.⁷8-chlorotheophylline may produce excitation through blocking adenosine receptors, reducing the drowsiness produced by diphenhydramine.¹³

Target	Actions	Organism
AHistamine H1 receptor	antagonist	Humans

Absorption

A 50 mg oral film coated tablet reaches a C_maxof 72.6 ng/mL with a T_maxof 2.7 hours.¹²A 100 mg suppository reaches a C_maxof 112.2 ng/mL with a T_maxof 5.3 hours.¹³

Volume of distribution

The volume of distribution of dimenhydrinate is 3-4 L/kg.¹²

Protein binding

Dimenhydrinate is 70-85% protein bound in plasma.¹²

Metabolism

Dimenhydrinate is a theoclate salt that separates intodiphenhydramineand8-chlorotheophylline.¹⁰diphenhydramine can either be N-glucuronidated by UGTs to diphenhydramine N-glucuronide or N-demethylated by CYP2D6, CYP1A2, CYP2C9, and CYP2C19 to N-desmethyldiphenhydramine.⁶N-desmethyldiphenhydramine can be N-demethylated again by the same enzymes to N,N-didesmethyldiphenhydramine, which undergoes oxidative deamination to form diphenylmethoxyacetic acid.⁶

Hover over products below to view reaction partners

• Dimenhydrinate
  • 8-chlorotheophylline+Diphenhydramine
    • N-Desmethyldiphenhydramine
      • N,N-Didesmethyldiphenhydramine
        • Diphenylmethoxyacetic acid
    • Diphenhydramine N-glucuronide

Route of elimination

Dimenhydrinate is predominantly eliminated in the urine.¹²1-3% of the dissociated diphenhydramine is eliminated in the urine unchanged, while 64% of diphenhydramine is eliminated in the urine as metabolites.¹³The elimination of dimenhydrinate has not been fully studied.¹³

Half-life

The plasma elimination half life of dimenhydrinate is 5-8 hours.¹²

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Infants and children experiencing an overdose may lead to hallucinations, convulsions, or death.¹⁰Adults experiencing an overdose may present with drowsiness, convulsions, coma, or respiratory depression.¹⁰Treat overdoses with symptomatic and supportive measures including mechanically assisted ventilation.¹⁰

In mice the oral LD₅₀is 203 mg/kg, while in rats it is 1320 mg/kg.¹⁰The intraperitoneal LD₅₀in mice is 149 mg/kg.¹⁰

Pathways

Not Available

Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with 1,2-Benzodiazepine.
Acetazolamide	The risk or severity of CNS depression can be increased when Acetazolamide is combined with Dimenhydrinate.
Acetophenazine	The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Acetophenazine.
Acrivastine	可以延长的风险或严重性高职院校学前教育专业creased when Acrivastine is combined with Dimenhydrinate.
Adenosine	可以延长的风险或严重性高职院校学前教育专业creased when Adenosine is combined with Dimenhydrinate.
Agomelatine	The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Agomelatine.
Ajmaline	可以延长的风险或严重性高职院校学前教育专业creased when Ajmaline is combined with Dimenhydrinate.
Alfentanil	The risk or severity of CNS depression can be increased when Alfentanil is combined with Dimenhydrinate.
Alfuzosin	可以延长的风险或严重性高职院校学前教育专业creased when Alfuzosin is combined with Dimenhydrinate.
Alimemazine	The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Alimemazine.

Identify potential medication risks

很容易与我们的药物intera 40药物进行比较ction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

• Avoid alcohol.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Diphenhydramine	salt	8GTS82S83M	58-73-1	ZZVUWRFHKOJYTH-UHFFFAOYSA-N
8-chlorotheophylline	salt	GE2UA340FM	85-18-7	RYIGNEOBDRVTHA-UHFFFAOYSA-N

Product Images

International/Other Brands

Gravol (Church & Dwight)/Vertirosan (Astellas)/Vomex A (Astellas)/Xamamina (Adilna)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Dimenhydrinate Inj 10mg/ml	Liquid	10 mg / mL	Intravenous	Astra Pharma Inc.	1986-12-31	1999-07-29
Dimenhydrinate Injection 50mg/ml	Solution	50 mg / mL	Intramuscular; Intravenous	Astra Zeneca	1986-12-31	2005-05-31
Dimenhydrinate Injection USP	Solution	50 mg / mL	Intramuscular; Intravenous	Sandoz Canada Incorporated	1973-12-31	Not applicable
Dimenhydrinate Injection USP	Solution	250 mg / 5 mL	Intramuscular; Intravenous	Hikma Canada Limited	2016-01-28	Not applicable
Dimenhydrinate Injection USP	Solution	50 mg / mL	Intramuscular; Intravenous	Hikma Canada Limited	2016-01-28	Not applicable
Dimenhydrinate Injection USP	Solution	10 mg / mL	Intravenous	Sandoz Canada Incorporated	1973-12-31	Not applicable
Dimenhydrinate Injection USP 250mg/5ml (50mg/ml)	Solution	50 mg / mL	Intramuscular; Intravenous	Teligent Ou	2008-06-26	2022-02-01
Dimenhydrinate Injection, USP	Solution	50 mg / mL	Intramuscular; Intravenous	Mylan Pharmaceuticals	1994-12-31	Not applicable
Gravol Im	Solution	50 mg / mL	Intramuscular	Church & Dwight Canada Corp	1953-12-31	Not applicable
Gravol IV Ampoules	Solution	10 mg / mL	Intravenous	Church & Dwight Canada Corp	1953-12-31	2008-07-30

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Dimenhydrinate	Injection, solution	50 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2004-11-29	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Ag-dimenhydrinate	Tablet	50 mg	Oral	Angita Pharma Inc.	Not applicable	Not applicable
Airmit Ace	Tablet	25 mg/1	Oral	Sato Pharmaceutical Co., Ltd.	2005-03-11	Not applicable
Anti-nauseant	Tablet	50 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Anti-nauseant	Tablet	50 mg	Oral	Pharmascience Inc	Not applicable	Not applicable
Anti-nauseant	Tablet	50 mg	Oral	Pharmascience Inc	2002-08-23	Not applicable
Anti-nauseant	Tablet	50 mg	Oral	Apotex Corporation	2013-07-02	Not applicable
Anti-nauseant	Tablet	50 mg	Oral	Vita Health Products Inc	2000-05-01	Not applicable
Anti-nauseant Liquid Gels	Capsule	50 mg	Oral	Vita Health Products Inc	2020-08-04	Not applicable
Anti-nauseant Tablet	Tablet	50 mg	Oral	Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.	1998-05-26	2008-08-07
Apo Dimenhydrinate Tab 50mg	Tablet	50 mg	Oral	Apotex Corporation	1977-12-31	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Arlevert 20 mg/40 mg Tabletten	Dimenhydrinate(40 mg)+Cinnarizine(20 mg)	Tablet	Oral	Hennig Arzneimittel Gmb H & Co Kg	2007-09-06	Not applicable
Gravergol Capsules	Dimenhydrinate(50 mg)+Caffeine(100 mg)+Ergotamine tartrate(1 mg)	Capsule	Oral	Can Med Pharma Inc.	1957-12-31	2011-12-07
Neo - Emedyl - Dragees	Dimenhydrinate(50 mg)+Caffeine(50 mg)	Tablet, sugar coated	Oral	Pharmazeutische Fabrik Montavit Gmb H	1965-05-20	Not applicable
Vertirosan Vitamin B6 - Manteldragees	Dimenhydrinate(50 mg)+Pyridoxine hydrochloride(25 mg)	Tablet, coated	Oral	Sigmapharm Arzneimittel Gmb H	1962-03-29	Not applicable
Vertirosan Vitamin B6 - Zäpfchen	Dimenhydrinate(50 mg)+Pyridoxine hydrochloride(50 mg)	Suppository	Rectal	Sigmapharm Arzneimittel Gmb H	1962-03-29	Not applicable
มาโนไดสิค	Dimenhydrinate(50 MG)+Pyridoxine(20 MG)	Tablet		บริษัท โรงงานเภสัชกรรมแหลมทองการแพทย์ จำกัด จำกัด	1986-12-30	Not applicable
เวนซิกซ์	Dimenhydrinate(50 MG)+Pyridoxine(10 MG)	Capsule		บริษัท โมเดิร์น ฟาร์มา จำกัด	2013-01-14	Not applicable
เวอร์ตามิน	Dimenhydrinate(25 MG)+Pyridoxine(25 MG)	Tablet, sugar coated	Oral	ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม	1985-04-02	Not applicable

Categories

ATC Codes

R06AA11 — Dimenhydrinate

• R06AA — Aminoalkyl ethers
• R06A — ANTIHISTAMINES FOR SYSTEMIC USE
• R06 — ANTIHISTAMINES FOR SYSTEMIC USE
• R — RESPIRATORY SYSTEM

R06AA61 — Dimenhydrinate, combinations

• R06AA — Aminoalkyl ethers
• R06A — ANTIHISTAMINES FOR SYSTEMIC USE
• R06 — ANTIHISTAMINES FOR SYSTEMIC USE
• R — RESPIRATORY SYSTEM

Drug Categories

• Alkaloids
• Amines
• Aminoalkyl Ethers
• Antiemetics
• Antihistamines for Systemic Use
• Autonomic Agents
• Benzene Derivatives
• Benzhydryl Compounds
• Central Nervous System Agents
• Central Nervous System Depressants
• Ethanolamine Derivatives
• Ethylamines
• Gastrointestinal Agents
• Heterocyclic Compounds, Fused-Ring
• Histamine Agents
• Histamine Antagonists
• Histamine H1 Antagonists
• Moderate Risk QTc-Prolonging Agents
• Neurotransmitter Agents
• Peripheral Nervous System Agents
• Pharmaceutical Preparations
• Purines
• Purinones
• QTc Prolonging Agents

Classification

Not classified

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

JB937PER5C

CAS number

523-87-5

InChI Key

NFLLKCVHYJRNRH-UHFFFAOYSA-N

InChI

InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)

IUPAC Name

8-chloro-1,3-dimethyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; [2-(diphenylmethoxy)ethyl]dimethylamine

SMILES

CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

References

Synthesis Reference

Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.

一般引用

1. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [Article]
2. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [Article]
3. Spealman RD: Psychomotor stimulant effects of methylxanthines in squirrel monkeys: relation to adenosine antagonism. Psychopharmacology (Berl). 1988;95(1):19-24. [Article]
4. Koch A, Cascorbi I, Westhofen M, Dafotakis M, Klapa S, Kuhtz-Buschbeck JP: The Neurophysiology and Treatment of Motion Sickness. Dtsch Arztebl Int. 2018 Oct 12;115(41):687-696. doi: 10.3238/arztebl.2018.0687. [Article]
5. FLEMING JF: New drug effective in motion sickness. Hosp Top. 1949 Mar;27(3):26. [Article]
6. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
7. FERMIN H, van DEINSE JB, HAMMELBURG E: The effect of dimenhydrinate upon the labyrinth; (an experimental study). Acta Otolaryngol. 1950 Dec;38(6):543-9. doi: 10.3109/00016485009118417. [Article]
8. FDA Approved Drug Products: Dimenhydrinate Oral Liquid (Discontinued) [Link]
9. Dailymed: Dimenhydrinate Oral Tablet [Link]
10. Dailymed: Dimenhydrinate Intramuscular and Intravenous Injection [Link]
11. US Patent: US2499058A [Link]
12. Sandoz Canada: Dimenhydrinate Intramuscular and Intravenous Injection [Link]
13. Heads of Medicines Agencies Public Assessment Report: Dimenhydrinate Oral Lozenge [Link]

External Links

Human Metabolome Database

HMDB0015120

KEGG Drug

D00520

PubChem Compound

441281

PubChem Substance

46504881

ChemSpider

10210

RxNav

3444

ChEBI

94848

ChEMBL

CHEMBL1200406

Therapeutic Targets Database

DAP000333

PharmGKB

PA449338

Drugs.com

Drugs.com Drug Page

Wikipedia

Dimenhydrinate

MSDS

Download (72 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	Post Operative Nausea and Vomiting (PONV)	1
4	Completed	Treatment	Gastroenteritis	1
4	Completed	Treatment	Nausea/Vertigo/Vomiting	1
4	Completed	Treatment	Pain/Postoperative pain	1
4	Completed	Treatment	Vertigo, Peripheral	1
3	Completed	Treatment	Vertigo, Peripheral	1
3	Not Yet Recruiting	Treatment	Perioperative Optimization	1
2	Completed	Treatment	Post Operative Nausea and Vomiting (PONV)	1
1	Completed	Treatment	Healthy Subjects (HS)	1
Not Available	Completed	Prevention	PONV in Laparoscopic Cholocystectomies	1

Pharmacoeconomics

Manufacturers

• App pharmaceuticals llc
• Baxter healthcare corp anesthesia and critical care
• Watson laboratories inc
• Wyeth ayerst laboratories
• Alra laboratories inc
• Heather drug co inc
• Nexgen pharma inc

Packagers

• APP Pharmaceuticals
• C.O. Truxton Inc.
• Consolidated Midland Corp.
• Dispensing Solutions
• Hospira Inc.
• Ivax Pharmaceuticals
• Major Pharmaceuticals
• Martin Surgical Supply
• Medisca Inc.
• Nexgen Pharma Inc.
• Pfizer Inc.
• Pharmacia Inc.
• Prescript Pharmaceuticals
• Southwood Pharmaceuticals

Dosage Forms

Form	Route	Strength
Tablet	Oral	25 mg/1
Suspension
Tablet, coated	Oral	50 mg
Solution	Oral	15 mg / 5 mL
Suppository	Rectal	50 mg
Injection, solution	Intramuscular; Intravenous	50 mg/1mL
Tablet	Oral
Tablet	Oral	50 mg/1
Tablet, film coated	Oral	50 mg/1
Liquid	Intravenous	10 mg / mL
Solution	Intramuscular; Intravenous	250 mg / 5 mL
Solution	Intramuscular; Intravenous	50 mg / mL
Solution	Intravenous	10 mg / mL
Liquid	Oral	15 mg / 5 mL
Tablet	Oral	50.0 mg
Tablet, chewable	Oral	50 mg/1
Tablet, chewable	Oral	25 mg/1
Tablet	Oral
Syrup	Oral	12.5 MG/5ML
Capsule	Oral
Capsule, liquid filled	Oral	50 mg/1
Capsule, extended release	Oral	75 mg
Tablet, chewable	Oral	50 mg
Tablet	Oral	15 mg
Solution	Intramuscular	50 mg / mL
Tablet, multilayer	Oral	100 mg
Tablet, extended release	Oral	75 mg
Suppository	Rectal	100 mg
Tablet	Oral	25 mg
Tablet, chewable	Oral	15 mg
Syrup	Oral	15 mg / 5 mL
Suppository	Rectal	25 mg
Syrup	Oral	25 mg/5ml
Syrup	Oral
Tablet, coated	Oral	50 mg/1
Tablet	Oral	0.05 g
Solution	Oral	0.25 g
Syrup	Oral	3 mg / mL
Gum, chewing	Oral
Gum, chewing	Oral	20 MG
Tablet, sugar coated	Oral
Tablet, coated	Oral	100 MG
Tablet, coated	Oral	25 MG
Suppository	Rectal
Injection, solution	Intramuscular; Intravenous	150 mg/ml
Injection, solution	Intramuscular; Intravenous	50 mg/ml
Solution / drops	Oral	92.5 mg/ml
Tablet, coated	Oral
Suppository	Rectal
Tablet, orally disintegrating	Sublingual
Suppository	Rectal	150 MG
Suppository	Rectal	70 MG
Suppository	Rectal	40 MG
Tablet, orally disintegrating	Sublingual	50 MG
Injection	Intramuscular; Intravenous	50 mg/ml
Injection	Intramuscular; Intravenous
Capsule	Oral	50 mg
Tablet, film coated	Oral	50 mg
Tablet
Capsule
Tablet, sugar coated	Oral
Solution		50 mg/1ml
Tablet	Oral	50 mg
Tablet, sugar coated	Oral	50 mg
Syrup	Oral	15 mg/5ml

Prices

Unit description	Cost	Unit
Dimenhydrinate 50 mg/ml vial	5.7USD	ml
Dimenhydrinate I.M. 50 mg/ml	1.17USD	ml
Meclizine 12.5 mg tablet	0.62USD	tablet
Dramamine less drowsy tablet	0.42USD	tablet
Dimenhydrinate I.V. 10 mg/ml	0.32USD	ml
Dramamine 50 mg tablet	0.28USD	tablet
Novamine 15% iv solution	0.09USD	ml
Dimenhydrinate 100% powder	0.07USD	g
Driminate 50 mg tablet	0.05USD	tablet
Dimenhydrinate 50 mg tablet	0.03USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	103-104	Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
water solubility	3000 mg/L	MERCK INDEX (1996); approx.

Predicted Properties

Property	Value	Source
Water Solubility	9.86 mg/mL	ALOGPS
logP	0.44	ALOGPS
logP	3.65	Chemaxon
logS	-1.3	ALOGPS
pKa (Strongest Basic)	8.87	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	12.47 Å2	Chemaxon
Rotatable Bond Count	6	Chemaxon
Refractivity	79.93 m3·mol-1	Chemaxon
Polarizability	30.02 Å3	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9975
Blood Brain Barrier	+	0.8551
Caco-2 permeable	+	0.5198
P-glycoprotein substrate	Substrate	0.7863
P-glycoprotein inhibitor I	Non-inhibitor	0.6923
P-glycoprotein inhibitor II	Inhibitor	0.6502
Renal organic cation transporter	Non-inhibitor	0.6507
CYP450 2C9 substrate	Non-substrate	0.7536
CYP450 2D6 substrate	Non-substrate	0.8181
CYP450 3A4 substrate	Substrate	0.7086
CYP450 1A2 substrate	Inhibitor	0.5287
CYP450 2C9 inhibitor	Non-inhibitor	0.6308
CYP450 2D6 inhibitor	Non-inhibitor	0.8589
CYP450 2C19 inhibitor	Non-inhibitor	0.5817
CYP450 3A4 inhibitor	Non-inhibitor	0.9028
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.5738
Ames test	Non AMES toxic	0.5629
Carcinogenicity	Non-carcinogens	0.7548
Biodegradation	Not ready biodegradable	0.8211
Rat acute toxicity	2.4087 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.5364
hERG inhibition (predictor II)	Inhibitor	0.5405

ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details 1.Histamine H1 receptor

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

General Function

Histamine receptor activity

Specific Function

In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...

Gene Name

HRH1

Uniprot ID

P35367

Uniprot Name

Histamine H1 receptor

分子量

55783.61 Da

References

1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [Article]

×

Identify potential medication risks

很容易与我们的药物intera 40药物进行比较ction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at April 30, 2023 03:04